Nestlé Health Science Acquires Seres Therapeutics' VOWST Division

Leading live biotherapeutics firm Nestlé Health Science has agreed to purchase Seres Therapeutics' VOWST division. Capital infusions for the agreement will take the form of an equity investment, a pre-paid milestone payment, and an upfront payment. In addition to possible future payments based on VOWST net sales objectives, Seres will receive installment payments in 2025. until the first quarter of 2025 and manufacturing support until the end of the same year, the firm will support continuous VOWST availability. The purchase is anticipated to close within the next ninety days, pending approval from Seres' shareholders and other usual conditions.

Through the utilisation of cultured live biotherapeutics, the sale provides a sizable amount of funds to assist Seres' pipeline progression and patient outcomes improvement in medically fragile groups. The funds will be utilised to develop the pipeline, improve the balance sheet, and repay the company's current loan facility, according to Seres President and CEO Eric Shaff. The business is also working on cultivating live biotherapeutic candidates for a variety of medically fragile patient populations, such as those who may have solid organ transplants, cancer neutropenia, and chronic liver illness. The treatment strategy developed by Seres may shield these patients from potentially fatal infections, opening up enormous business prospects.